Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - AVEO

Drug Profile

Research programme: monoclonal antibody therapeutics - AVEO

Alternative Names: AV-232; AV-323; AV-325; AV-353; AV-368; AV-369; AV-370; AV-371; AV-378; AV-380

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St Vincents Hospital, Sydney
  • Developer AVEO Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Growth differentiation factor 15 inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Notch signalling pathway inhibitors; Notch-3 receptor antagonists; Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia; Pulmonary arterial hypertension

Highest Development Phases

  • Preclinical Cachexia; Cancer; Pulmonary arterial hypertension

Most Recent Events

  • 15 May 2019 AV-380 is still in preclinical trials for Cachexia in USA (Parenteral)
  • 23 Apr 2019 AVEO Pharmaceuticals plans IND-enabling toxicology studies in Cachexia in mid-2019
  • 05 Mar 2019 AVEO Pharmaceuticals plans clinical development in Cachexia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top